Wgi Dm LLC Buys 267,888 Shares of Icon Plc $ICLR

Wgi Dm LLC increased its position in shares of Icon Plc (NASDAQ:ICLR) by 26.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,277,980 shares of the medical research company’s stock after buying an additional 267,888 shares during the quarter. Icon accounts for 0.0% of Wgi Dm LLC’s portfolio, making the stock its 4th biggest holding. Wgi Dm LLC’s holdings in Icon were worth $223,646,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ICLR. Allworth Financial LP lifted its position in Icon by 64.4% in the second quarter. Allworth Financial LP now owns 1,396 shares of the medical research company’s stock worth $203,000 after purchasing an additional 547 shares during the period. Geode Capital Management LLC increased its holdings in Icon by 2.6% in the 2nd quarter. Geode Capital Management LLC now owns 84,370 shares of the medical research company’s stock valued at $12,272,000 after buying an additional 2,159 shares during the period. SG Americas Securities LLC increased its holdings in Icon by 12.3% in the 2nd quarter. SG Americas Securities LLC now owns 15,962 shares of the medical research company’s stock valued at $2,322,000 after buying an additional 1,743 shares during the period. Raiffeisen Bank International AG raised its stake in shares of Icon by 7.1% in the 2nd quarter. Raiffeisen Bank International AG now owns 7,500 shares of the medical research company’s stock valued at $1,094,000 after buying an additional 500 shares in the last quarter. Finally, Portside Wealth Group LLC boosted its position in shares of Icon by 11.9% during the 2nd quarter. Portside Wealth Group LLC now owns 1,816 shares of the medical research company’s stock valued at $264,000 after acquiring an additional 193 shares in the last quarter. 95.61% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ICLR has been the subject of several recent research reports. Mizuho set a $216.00 price target on shares of Icon in a research report on Friday, January 9th. Rothschild & Co Redburn set a $100.00 price objective on Icon and gave the company a “neutral” rating in a research note on Tuesday, February 17th. Leerink Partners reissued a “market perform” rating and issued a $105.00 target price on shares of Icon in a report on Thursday, February 12th. Zacks Research downgraded Icon from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 25th. Finally, Jefferies Financial Group set a $135.00 price target on Icon and gave the company a “buy” rating in a research note on Monday, February 23rd. Six research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Icon currently has a consensus rating of “Hold” and an average target price of $146.80.

Icon Stock Performance

NASDAQ ICLR opened at $97.14 on Thursday. Icon Plc has a 1-year low of $66.57 and a 1-year high of $211.00. The company has a 50 day moving average of $137.95 and a 200-day moving average of $163.84. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31. The firm has a market cap of $7.85 billion, a price-to-earnings ratio of 13.14, a PEG ratio of 2.57 and a beta of 1.35.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.